Arming Immune Cell Therapeutics with Polymeric Prodrugs
- 8 December 2021
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (9) , 2101944-e2101944
Abstract
Engineered immune cells are an exciting therapeutic modality, which survey and attack tumors. Backpacking strategies exploit cell targeting capabilities for delivery of drugs to combat tumors and their immune‐suppressive environments. Here, a new platform for arming cell therapeutics through dual receptor and polymeric prodrug engineering is developed. Macrophage and T cell therapeutics are engineered to express a bioorthogonal single chain variable fragment receptor. The receptor binds a fluorescein ligand that directs cell loading with ligand‐tagged polymeric prodrugs, termed “drugamers.” The fluorescein ligand facilitates stable binding of drugamer to engineered macrophages over 10 days with 80% surface retention. Drugamers also incorporate prodrug monomers of the phosphoinositide‐3‐kinase inhibitor, PI‐103. The extended release of PI‐103 from the drugamer sustains antiproliferative activity against a glioblastoma cell line compared to the parent drug. The versatility and modularity of this cell arming system is demonstrated by loading T cells with a second fluorescein‐drugamer. This drugamer incorporates a small molecule estrogen analog, CMP8, which stabilizes a degron‐tagged transgene to provide temporal regulation of protein activity in engineered T cells. These results demonstrate that this bioorthogonal receptor and drugamer system can be used to arm multiple immune cell classes with both antitumor and transgene‐activating small molecule prodrugs.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R21AI149400)
This publication has 69 references indexed in Scilit:
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T CellsClinical Cancer Research, 2013
- Destabilizing Domains Derived from the Human Estrogen ReceptorJournal of the American Chemical Society, 2012
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011
- Therapeutic cell engineering with surface-conjugated synthetic nanoparticlesNature Medicine, 2010
- A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibitionBiochemical Journal, 2008
- Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiersJournal of Controlled Release, 2008
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesJournal of Clinical Investigation, 2008
- A Structure-Guided Approach to an Orthogonal Estrogen-Receptor-Based Gene Switch Activated by Ligands Suitable for in Vivo StudiesJournal of Medicinal Chemistry, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006